Pharmacoeconomic Analysis of Bemiparin and Enoxaparin as Prophylaxis for Venous Thromboembolism in Total Knee Replacement Surgery
Purchase on Springer.com
$49.95 / €39.95 / £34.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Introduction: Low molecular weight heparins are effective and have a good tolerability profile as first-line prophylaxis for venous thromboembolism (VTE) in major orthopaedic surgery. However, pharmacological inequivalence within the class could lead to differences in cost-effectiveness ratios.
Objective: To quantify the potential economic impact of subcutaneous bemiparin sodium 3500 IU/day compared with enoxaparin sodium 40 mg/day as prophylaxis for VTE in patients undergoing total knee replacement (TKR) surgery, considering both in-hospital and post-discharge outcomes and costs during 6 weeks of postoperative follow-up.
Methods: A cost-effectiveness analysis was performed using a decision modelling approach. The results were expressed in terms of costs and incremental cost effectiveness in ® (2002 values). The treatment costs (hospital stay, physician services, drug administration) and costs incurred due to complications such as pulmonary embolism and/or proximal deep vein thrombosis, bleeding events, wound haematoma and thrombocytopenia were considered for this analysis. The target population comprised all adult patients undergoing TKR surgery included in a previous clinical trial (n = 381). The study was conducted in the setting of the Spanish National Health System. The time horizon chosen was 6 weeks.
Results: Bemiparin provided cost savings of ®144.48 per patient compared with enoxaparin when costs derived from treatment and complications during the 6-week postoperative period were considered (®4675.01 vs ®4819.49). Pharmacy costs per patient were lower for bemiparin during hospital stay (®43.34 vs ®50.20; difference, ®-6.86) and for post-discharge prophylaxis (®68.63 vs ®87.78; difference ®-19.15). Bemiparin was calculated to avoid 42 additional VTE events per 1000 patients treated at 6 weeks. The incremental cost-effectiveness analysis indicated that bemiparin was dominant over enoxaparin, producing better outcomes and cost savings. The sensitivity analysis supported the cost effectiveness of bemiparin in all the ranges tested for complications and costs.
Conclusions: Our model suggests, based on its underlying assumptions and data, that bemiparin may be more cost effective than enoxaparin for thromboprophylaxis in total knee replacement surgery in the Spanish healthcare setting.
- Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001 Jan; 119 Suppl. 1: 132S–75S CrossRef
- Nicolaides AN, Breddin HK, Fareed J, et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001 Mar; 20 (1): 1–37 CrossRef
- Fareed J, Hoppensteadt D, Schultz C, et al. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile. CUff Pharm Des 2004; 10 (9): 983–99 CrossRef
- Nenci GC. Low-molecular-weight heparins: are interchangeable? No. J Thromb Haemost 2003 Jan; 1 (1): 12–3 CrossRef
- Michalis LK, Katsouras CS, Papamichael N, et al. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am Heart J 2003 Aug; 146 (2): 304–10 CrossRef
- Nightingale SL. From the Food and Drug Administration. JAMA 1993 Oct 13; 270 (14): 1672
- Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001 Jan; 119 Suppl. 1: 64S–94S CrossRef
- Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am ColI Cardiol1999 Sept; 34 (3): 890–911
- Planes A. Review on bemiparin sodium — a new second generation low-molecular-weight heparin — and its applications in venous thromboembolism. Expert Opin Pharmacother 2003 Sept; 4 (9): 1551–61
- Kakkar VV, Howes J, Sharma V, et al. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group. Thromb Haemost 2000 Apr; 83 (4): 523–9
- Navarro-Quilis A, Castellet E, Rocha E, et al. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. J Thromb Haemost 2003 Mar; 1 (3): 425–32 CrossRef
- Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. Panel of Cost-Effectiveness in Health and Medicine. JAMA 1996 Oct 9; 276 (14): 1172–7 CrossRef
- Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276: 1253–8 CrossRef
- Drummond MF, Richardson WS, O’Brien BJ, et al. Users’ guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1997 May 21; 277 (19): 1552–7 CrossRef
- Gold MR, Siegel JE, Russell LB, et al. editors. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Press; 1996
- Order of 26th December 2001 of the General Section of the National Healthcare Institute, on the revision of the prices that healthcare centres mist apply for the services rendered in the cases when the sums mist be requested from third parties who are obliged to payor from users not entitled to healthcare assistance form the National Health System. BOE, 2001; 5: 637–9 [in Spanish]. Available from URL: http://www.boe.es [Accessed 2003 Oct 31]
- Foral Order 83/2002, of 15th May, by the Healthcare Advisor, pursuant to which the tariffs for services rendered in the Healthcare Sentences of Servicio Navarro de Salud-Osasunbidea are approved. Boletín Oficial de Navarra, 2002; 91: 6530–41 [in Spanish]. Available from URL: http://www.cfnavarra.es [Accessed 2003 Oct 31]
- General Council of Official Associations of Pharmacists. Catalogue of Pharmaceutical Products, Madrid: General Council of Official Associations of Pharmacists, 2002
- Gould MK, Dembitzer AD, Sanders GD, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med 1999 May 18; 130 (10): 789–99
- Abad JI, Gómez-Outes A, Martínez-González J, et al. Observational study of bemiparin, first dose administered 6 hours after surgery, in hip or knee arthroplasty surgery [abstract]. Pathophysiol Haemost Thromb 2003; 33 Suppl. 2: 73
- Bonal J, Gisbert R. Pharmacoeconomic analysis of prophylaxis of venous thromboembolic disease in patients undergoing hip arthroplasty [in Spanish]. Revista Española de Farmacoeconomía 2000 Mar; 1: 17–26
- The European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products. Minimum SPC Wording for Unfractionated Heparins and Low Molecular Weight Heparins regarding the Risk of Epidural or Spinal Haematoma agreed by the PhVWP in November 2000. EMEAlCPMPlPhVWP/4452/00; Available from URL: http://www.emea.eu.int [Accessed 2003 Oct 31]
- Lumpkin MM. FDA public health advisory. Anesthesiology 1998 Feb; 88 (2): 27A-8A CrossRef
- Pharmacoeconomic Analysis of Bemiparin and Enoxaparin as Prophylaxis for Venous Thromboembolism in Total Knee Replacement Surgery
Volume 22, Issue 13 , pp 885-894
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. University Clinic of Navarra, Pamplona, Spain
- 2. Laboratorios Farmacèuticos Rovi, S.A., Madrid, Spain
- 3. Hospital Vall d’Hebròn, Barcelona, Spain
- 4. Clinique Radio-Chirurgicale du Mail, La Rochelle, France